PL1664036T3 - Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 - Google Patents

Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4

Info

Publication number
PL1664036T3
PL1664036T3 PL04744319T PL04744319T PL1664036T3 PL 1664036 T3 PL1664036 T3 PL 1664036T3 PL 04744319 T PL04744319 T PL 04744319T PL 04744319 T PL04744319 T PL 04744319T PL 1664036 T3 PL1664036 T3 PL 1664036T3
Authority
PL
Poland
Prior art keywords
agonistic activity
receptor agonistic
benzimidazolone compounds
benzimidazolone
compounds
Prior art date
Application number
PL04744319T
Other languages
English (en)
Inventor
Satoru Iguchi
Yasuhiro Katsu
Hiroki Sone
Chikara Uchida
Takashi Kojima
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PL1664036T3 publication Critical patent/PL1664036T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Manufacturing & Machinery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Ceramic Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL04744319T 2003-09-03 2004-08-20 Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4 PL1664036T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50014403P 2003-09-03 2003-09-03
EP04744319A EP1664036B1 (en) 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-ht4 receptor agonistic activity
PCT/IB2004/002741 WO2005021539A1 (en) 2003-09-03 2004-08-20 Benzimidazolone compounds having 5-ht4 receptor agonistic activity

Publications (1)

Publication Number Publication Date
PL1664036T3 true PL1664036T3 (pl) 2012-04-30

Family

ID=34272920

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04744319T PL1664036T3 (pl) 2003-09-03 2004-08-20 Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4

Country Status (39)

Country Link
US (2) US7776885B2 (pl)
EP (1) EP1664036B1 (pl)
JP (1) JP3983269B1 (pl)
KR (1) KR100738784B1 (pl)
CN (1) CN100482659C (pl)
AP (1) AP2184A (pl)
AR (1) AR045552A1 (pl)
AT (1) ATE539077T1 (pl)
AU (1) AU2004268840B9 (pl)
BR (1) BRPI0414105B8 (pl)
CA (1) CA2537127C (pl)
CR (1) CR8267A (pl)
CY (1) CY1112321T1 (pl)
DK (1) DK1664036T3 (pl)
EA (1) EA009457B1 (pl)
EC (1) ECSP066407A (pl)
ES (1) ES2377484T3 (pl)
GE (1) GEP20084527B (pl)
GT (1) GT200400174A (pl)
HR (1) HRP20120077T1 (pl)
IL (3) IL173705A (pl)
IS (1) IS8289A (pl)
MA (1) MA28021A1 (pl)
MX (1) MXPA06002550A (pl)
NL (1) NL1026959C2 (pl)
NO (1) NO20061519L (pl)
OA (1) OA13248A (pl)
PA (1) PA8610601A1 (pl)
PE (1) PE20050874A1 (pl)
PL (1) PL1664036T3 (pl)
PT (1) PT1664036E (pl)
RS (1) RS20060145A (pl)
SI (1) SI1664036T1 (pl)
TN (1) TNSN06073A1 (pl)
TW (1) TW200510332A (pl)
UA (1) UA86204C2 (pl)
UY (1) UY28496A1 (pl)
WO (1) WO2005021539A1 (pl)
ZA (1) ZA200601324B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE241351T1 (de) 1996-07-24 2003-06-15 Warner Lambert Co Isobutylgaba und dessen derivate zur schmerzbehandlung
GB0211230D0 (en) 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
MXPA06002550A (es) * 2003-09-03 2006-06-20 Pfizer Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4.
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
BRPI0512046A (pt) 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
EP1807422B1 (en) 2004-11-05 2009-09-02 Theravance, Inc. 5-ht4 receptor agonist compounds
DE602005014566D1 (de) 2004-11-05 2009-07-02 Theravance Inc Chinolinon-carboxamid-verbindungen
CA2588037A1 (en) 2004-12-22 2006-06-29 Theravance, Inc. Indazole-carboxamide compounds
EA012615B1 (ru) 2005-02-22 2009-10-30 Пфайзер Инк. Производные оксииндола в качестве агонистов 5-htрецептора
AU2006218603A1 (en) 2005-03-02 2006-09-08 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
ATE493391T1 (de) 2005-03-15 2011-01-15 Pfizer Benzimidazolonderivate als cb2-rezeptor-liganden
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
EP1902053B1 (en) * 2005-06-07 2011-01-12 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-ht4 receptor agonists
WO2007036718A2 (en) 2005-09-30 2007-04-05 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
DE602006019119D1 (de) * 2005-09-30 2011-02-03 Glaxo Group Ltd Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
EP1937670A1 (en) * 2005-09-30 2008-07-02 Glaxo Group Limited Benzimidazolones which have activity at m1 receptor
JP2009513672A (ja) * 2005-10-31 2009-04-02 ブレインセルス,インコーポレイティド 神経発生のgaba受容体媒介調節
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
TW200736227A (en) * 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
KR20140147142A (ko) * 2006-01-24 2014-12-29 가부시키가이샤 아루떼꾸 우에노 바이-사이클릭 화합물을 함유하는 약학적 조성물 및 바이-사이클릭 화합물의 안정화 방법
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
US20080318964A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched eszopiclone
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(adhd)의 치료 방법
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
ES2640752T3 (es) * 2010-02-12 2017-11-06 Askat Inc. Agonistas del receptor 5-HT4 para el tratamiento de la demencia
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
WO2012074721A2 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of serotonin receptor antagonists by microinjection systems
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
TW201348235A (zh) 2012-05-03 2013-12-01 Novartis Ag 作爲格瑞啉受體促效劑之3-螺環哌啶衍生物
US20180344648A1 (en) * 2015-11-30 2018-12-06 Piramal Enterprises Limited Clobazam tablet formulation and process for its preparation
US20230381109A1 (en) * 2020-10-23 2023-11-30 Hk Inno.N Corporation Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63716A (en) * 1867-04-09 Improved cheery stoner
CH566987A5 (pl) * 1972-04-21 1975-09-30 Ciba Geigy Ag
US3945953A (en) * 1972-04-21 1976-03-23 Ciba-Geigy Corporation ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use
DE3336024A1 (de) * 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
US5223511A (en) * 1987-09-23 1993-06-29 Boehringer Ingelheim Italia S.P.A. Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0522914A1 (fr) * 1991-06-27 1993-01-13 Synthelabo Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
GB9204565D0 (en) 1992-03-03 1992-04-15 Smithkline Beecham Plc Pharmaceuticals
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
JPH08502741A (ja) * 1992-11-05 1996-03-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5−ht▲下4▼レセプターアンタゴニスト用のピペリジン誘導体
TW252206B (pl) * 1993-09-01 1995-07-21 Philips Electronics Nv
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO1999012903A1 (en) 1997-09-09 1999-03-18 Du Pont Pharmaceuticals Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
US6420410B1 (en) * 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
JPWO2002053568A1 (ja) * 2000-12-28 2004-05-13 持田製薬株式会社 スピロ結合を有する三環系化合物を有効成分とするコレステロール生合成阻害剤
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
MXPA06002550A (es) * 2003-09-03 2006-06-20 Pfizer Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4.
BRPI0512046A (pt) * 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
UA86204C2 (uk) 2009-04-10
DK1664036T3 (da) 2012-02-13
MA28021A1 (fr) 2006-07-03
NL1026959C2 (nl) 2006-01-23
IL205600A0 (en) 2010-11-30
CA2537127C (en) 2011-04-05
IL173705A0 (en) 2006-07-05
CA2537127A1 (en) 2005-03-10
EA009457B1 (ru) 2007-12-28
HK1093338A1 (zh) 2007-03-02
CY1112321T1 (el) 2015-12-09
IL173705A (en) 2013-04-30
EP1664036A1 (en) 2006-06-07
CN100482659C (zh) 2009-04-29
NL1026959A1 (nl) 2005-03-07
AP2006003536A0 (en) 2006-04-30
EA200600327A1 (ru) 2006-08-25
ECSP066407A (es) 2006-09-18
NO20061519L (no) 2006-06-01
MXPA06002550A (es) 2006-06-20
PT1664036E (pt) 2012-02-16
AR045552A1 (es) 2005-11-02
BRPI0414105A (pt) 2006-11-21
IL205599A0 (en) 2010-11-30
AU2004268840B9 (en) 2011-02-03
BRPI0414105B8 (pt) 2021-05-25
WO2005021539A1 (en) 2005-03-10
US7776885B2 (en) 2010-08-17
GT200400174A (es) 2005-05-02
ES2377484T3 (es) 2012-03-28
KR20060087540A (ko) 2006-08-02
CR8267A (es) 2006-11-21
AU2004268840A1 (en) 2005-03-10
PA8610601A1 (es) 2005-03-28
KR100738784B1 (ko) 2007-07-12
RS20060145A (sr) 2008-06-05
AU2004268840B2 (en) 2010-09-23
TW200510332A (en) 2005-03-16
ZA200601324B (en) 2007-05-30
JP2007533613A (ja) 2007-11-22
BRPI0414105B1 (pt) 2018-08-14
US20050148573A1 (en) 2005-07-07
ATE539077T1 (de) 2012-01-15
AP2184A (en) 2010-12-02
SI1664036T1 (sl) 2012-03-30
HRP20120077T1 (hr) 2012-02-29
PE20050874A1 (es) 2005-10-26
UY28496A1 (es) 2005-04-29
TNSN06073A1 (en) 2007-10-03
IS8289A (is) 2006-02-09
GEP20084527B (en) 2008-11-10
EP1664036B1 (en) 2011-12-28
US20100273794A1 (en) 2010-10-28
JP3983269B1 (ja) 2007-09-26
CN1845922A (zh) 2006-10-11
OA13248A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
IL205599A0 (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
IL174990A0 (en) Compounds having crth2 antagonist activity
AU2002353403A8 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
IL178086A0 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
GB0325093D0 (en) Fiberglass nonwoven catalyst
AU153030S (en) Holder for showers
NO20013443L (no) Triazolforbindelser med dopamin-D3-reseptoraktivitet
PL371596A1 (pl) Zastosowanie związków skutecznych jako selektywnemodulatory receptora opiatowego
GB0306731D0 (en) Activity monitor
PT1562595E (pt) Éteres diarílicos como antagonistas de receptor de opióides
TW543509U (en) Improved structure for water sprinkle-nozzle
DE50303910D1 (de) Rinnenschuss
EP1616880A4 (en) LIGAND WITH AGONISTIC ACTIVITY AGAINST A MUTED RECEPTOR
IS2897B (is) Efnasambönd sem hamla gegn virkni kalkviðtaka
GB0226227D0 (en) Receptors
AU2003287219A8 (en) Il-8 receptor antagonists
SG131946A1 (en) Ccr3 receptor antagonists
IL173337A0 (en) Receptor
AU149648S (en) Shower unit
ZA200804010B (en) Carbamate compounds as 5-HT4 receptor agonists
GB0215389D0 (en) Receptor
GB0223399D0 (en) Receptors
GB2402316B (en) Bed for pets
GB0321998D0 (en) Receptor
AU149317S (en) Sanitary ware for pets